Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Pandoraon Aug 20, 2020 1:28am
261 Views
Post# 31432051

Pulmonary Fibrosis Therapeutic -- very familiar story.

Pulmonary Fibrosis Therapeutic -- very familiar story.

If you get COVID-19, $iBio's therapeutic STOPS, BLOCKS, and REVERSES what causes you to die!!!

Update-4: Over the next few hours, I will prove the headline, and solve why COVID-19 is a pandemic, and how IBIO-100 makes it an ailment.

NEW STUDIES SHOW COVID-19 infected elderly die from irreversible Idiopathic Pulmonary Fibrosis. If we treat COVID-19 and STOP the onset of debilitating fibrosis, we can STOP the elderly from dying. If the elderly STOP dying, THE GREAT PANDEMIC of COVID-19 then becomes an AILMENT like Gout or Irritable Bowel Syndrome, AND THEN our need to social distance will be as great as our need for a Russian-made Zombie vaccine.

The Flow Follows and shows how a vaccine will not cure COVID-19:

New Clinical Trial Data attribute COVID-19 elderly death to the to the onset of a form of progressive Pulmonary Fibrosis(IPF).

While current trials seek to cure COVID-19 through antagonizing the IL-6 receptor, 2/3rds of patients GAIN progressive lung damage. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228727/

This data exhibits how some current COVID-19 therapeutics MIGHT cure some from COVID-19, but while doing so, they also permanently scar the lungs.

The knowledge of the cause of death is recent. Johnson and Johnson just got a Billion dollars for the lung scarring il-6 trials mentioned below- Regeneron over 600 Million.

These FAILED government funded clinical trials include pharmaceuticals from Johnson and Johnson(tocilizumab), Regeneron and Sanofi(sarilumab). (NCT04332913; NCT04322773; NCT04331795; NCT04315298; NCT04324021)

Other current drugs only come in ORAL form.

Two commercially available previously FDA approved therapeutics Boehringer Ingelheim's nintedanib(OFEV), and Genentech's pirfenidone(Esbriet) ONLY come in an oral treatment. An oral treatment does not work when you have a ventilator tube almost a foot down your throat.

Continued on this link:

https://www.reddit.com/r/IBIO/comments/icva2o/if_you_get_covid19_ibios_therapeutic_stops_blocks/

<< Previous
Bullboard Posts
Next >>